Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for UX701 in Rare diseases, Wilson's disease. The expected timing is based on the latest available company guidance and may change.
Cyprus2+ Study. 07/2023- DSMB meeting w/ recommendation of escalating to 2nd dose. 10/3/2024- Provided trial update. 2/13/25- Enrollment completion in H2 2025. 11/04/25:- Completed Cohort 4 enrollment; UX701 Cyprus2+ data expected H1 2026. 01/12/26:- Reiterated UX701 Cyprus2+ dose-finding Cohort 4 complete; data expected H1 2026. 05/05/26:- Cyprus2+ cohort4 enrollment complete; dose-finding stage data now expected sometime in 2026, timing broadened from H1. 08/04/26:- Cyprus2+ cohort 4 complete; dose-finding data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.